Global Autologous Cell Therapy Market 2020-2024
SKU ID : TNV-15466228 | Publishing Date : 17-Mar-2020 | No. of pages : 120
Detailed TOC of Global Autologous Cell Therapy Market 2020-2024
•Executive Summaryo Market Overview
•Market Landscape
o Market ecosystem
o Value chain analysis
•Market Sizing
o Market definition
o Market segment analysis
o Market size 2019
o Market outlook: Forecast for 2019 - 2024
•Five Forces Analysis
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
•Market Segmentation by Other 1
o Market segments
o Comparison by Other1 placement
o Autologous stem cell therapy - Market size and forecast 2019-2024
o Autologous cellular immunotherapies - Market size and forecast 2019-2024
o Market opportunity by Other1
•Customer landscape
o Overview
•Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America - Market size and forecast 2019-2024
o Europe - Market size and forecast 2019-2024
o APAC - Market size and forecast 2019-2024
o South America - Market size and forecast 2019-2024
o MEA - Market size and forecast 2019-2024
o Key leading countries
o Market opportunity by geography
•Drivers, Challenges, and Trends
o Market drivers
o Volume driver - Demand led growth
o Volume driver - Supply led growth
o Volume driver - External factors
o Volume driver - Demand shift in adjacent markets
o Price driver - Inflation
o Price driver - Shift from lower to higher-priced units
o Market challenges
o Market trends
•Vendor Landscape
o Overview
o Landscape disruption
o Vendor Analysis
•Vendors covered
o Market positioning of vendors
o Bayer AG
o Brainstorm Cell Therapeutics Inc.
o Daiichi Sankyo Co. Ltd.
o FUJIFILM Holdings Corp.
o Holostem Terapie Avanzate Srl
o Osiris Therapeutics Inc.
o Takeda Pharmaceutical Co. Ltd.
o Teva Pharmaceutical Industries Ltd.
o Sumitomo Chemical Co. Ltd.
o Vericel Corp.
•Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations
•1.Key Finding 1
•2.Key Finding 2
•3.Key Finding 3
•4.Key Finding 5
•5.Key Finding 6
•6.Key Finding 7
•7.Key Finding 8
•8.Market in focus
•10.Parent market
•13.Market characteristics
•15.Offerings of vendors included in the market definition
•17.Market segments
•22.Global - Market size and forecast 2019 - 2024 ($ million)
•23.Global market: Year-over-year growth 2019 - 2024 (%)
•24.Five forces analysis 2019 & 2024
•26.Bargaining power of buyers
•27.Bargaining power of suppliers
•28.Threat of new entrants
•29.Threat of substitutes
•30.Threat of rivalry
•32.Market condition - Five forces 2019
•33.Other1 placement - Market share 2019-2024 (%)
•34.Comparison by Other1 placement
•35.Autologous stem cell therapy - Market size and forecast 2019-2024 ($ million)
•36.Autologous stem cell therapy - Year-over-year growth 2019-2024 (%)
•37.Autologous cellular immunotherapies - Market size and forecast 2019-2024 ($ million)
•38.Autologous cellular immunotherapies - Year-over-year growth 2019-2024 (%)
•39. Market opportunity by Other1
•40.Customer landscape
•41.Market share by geography 2019-2024 (%)
•42.Geographic comparison
•44.North America - Market size and forecast 2019-2024 ($ million)
•45.North America - Year-over-year growth 2019-2024 (%)
•47.Europe - Market size and forecast 2019-2024 ($ million)
•48.Europe - Year-over-year growth 2019-2024 (%)
•50.APAC - Market size and forecast 2019-2024 ($ million)
•51.APAC - Year-over-year growth 2019-2024 (%)
•53.South America - Market size and forecast 2019-2024 ($ million)
•54.South America - Year-over-year growth 2019-2024 (%)
•56.MEA - Market size and forecast 2019-2024 ($ million)
•57.MEA - Year-over-year growth 2019-2024 (%)
•58.Key leading countries
•59.Market opportunity by geography ($ million)
•60.Impact of drivers and challenges
•61.Vendor landscape
•63.Landscape disruption
•65.Industry risks
•67.Vendors covered
•69.Market positioning of vendors
•71.Bayer AG - Overview
•72.Bayer AG - Business segments
•73.Bayer AG - Key offerings
•74.Bayer AG - Key customers
•75.Bayer AG - Segment focus
•77.Brainstorm Cell Therapeutics Inc. - Overview
•78.Brainstorm Cell Therapeutics Inc. - Product and service
•79.Brainstorm Cell Therapeutics Inc. - Key offerings
•80.Brainstorm Cell Therapeutics Inc. - Key customers
•81.Brainstorm Cell Therapeutics Inc. - Segment focus
•83.Daiichi Sankyo Co. Ltd. - Overview
•84.Daiichi Sankyo Co. Ltd. - Business segments
•85.Daiichi Sankyo Co. Ltd. - Key offerings
•86.Daiichi Sankyo Co. Ltd. - Key customers
•87.Daiichi Sankyo Co. Ltd. - Segment focus
•89.FUJIFILM Holdings Corp. - Overview
•90.FUJIFILM Holdings Corp. - Business segments
•91.FUJIFILM Holdings Corp. - Key offerings
•92.FUJIFILM Holdings Corp. - Key customers
•93.FUJIFILM Holdings Corp. - Segment focus
•95.Holostem Terapie Avanzate Srl - Overview
•96.Holostem Terapie Avanzate Srl - Product and service
•97.Holostem Terapie Avanzate Srl - Key offerings
•98.Holostem Terapie Avanzate Srl - Key customers
•99.Holostem Terapie Avanzate Srl - Segment focus
•101.Osiris Therapeutics Inc. - Overview
•102.Osiris Therapeutics Inc. - Product and service
•103.Osiris Therapeutics Inc. - Key offerings
•104.Osiris Therapeutics Inc. - Key customers
•105.Osiris Therapeutics Inc. - Segment focus
•107.Takeda Pharmaceutical Co. Ltd. - Overview
•108.Takeda Pharmaceutical Co. Ltd. - Product and service
•109.Takeda Pharmaceutical Co. Ltd. - Key offerings
•110.Takeda Pharmaceutical Co. Ltd. - Key customers
•111.Takeda Pharmaceutical Co. Ltd. - Segment focus
•113.Teva Pharmaceutical Industries Ltd. - Overview
•114.Teva Pharmaceutical Industries Ltd. - Business segments
•115.Teva Pharmaceutical Industries Ltd. - Key offerings
•116.Teva Pharmaceutical Industries Ltd. - Key customers
•117.Teva Pharmaceutical Industries Ltd. - Segment focus
•119.Sumitomo Chemical Co. Ltd. - Overview
•120.Sumitomo Chemical Co. Ltd. - Business segments
•121.Sumitomo Chemical Co. Ltd. - Key offerings
•122.Sumitomo Chemical Co. Ltd. - Key customers
•123.Sumitomo Chemical Co. Ltd. - Segment focus
•125.Vericel Corp. - Overview
•126.Vericel Corp. - Product and service
•127.Vericel Corp. - Key offerings
•128.Vericel Corp. - Key customers
•129.Vericel Corp. - Segment focus
•131.Currency conversion rates for US$
•132.Research Methodology
•133.Validation techniques employed for market sizing
•134.Information sources
•135. List of abbreviations